

Alector Corporate Overview

February 2024

Forward-Looking Statement

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "should," "will" or the negative of these terms or other similar expressions. Forward-looking statements contained in this presentation also include, but are not limited to, statements regarding: our future financial condition, including the sufficiency of cash to fund operations in to 2H 2026; results of operations; business strategy and plans; the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates; our plans, timelines and expectations related to our product candidates and our other clinical and preclinical programs, including with respect to the availability of data, the initiation of future clinical trials and plans and expectations regarding planned regulatory filings with respect to such programs; expectations regarding the timing and financial benefit of our collaborations; and objectives of management for future operations, as well as statements regarding industry trends.

We, Alector, Inc. ("Alector"), have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: Alector's plans relating to its research programs and the development and monufacturing of its product candidates; the ability of Alector's clinical trials to demonstrate safety and efficacy of its product candidates, and other positive results; the timing and focus of Alector's clinical trials, and the reporting of data from those trials; Alector's plans relating to commercializing its product candidates, if approved, including the geographic areas of focus and sales strategy; the expected potential benefits of strategic collaborations with third parties and Alector's ability to attract collaborators with development, regulatory and commercialization expertise; Alector's estimates of the number of patients in the United States, the European Union and world-wide who suffer from the diseases it is targeting and the number of patients in the United States, che curves and its product candidates; the approtantity for Alector's product candidates; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy, and therapeutic effects of Alector's product candidates; the timing or likelihood of regulatory filings and approvals, including Alector's relating to the further development and manufacturing of its product candidates, including additional indications that it may pursue; existing and future regulations and regulatory developments; Alector's product candidates; the timing or likelihood of regulatory filings and approvals, including Alector's relating to the further development and manufacturing of its product candidates, including additional indications that it m

This presentation also contains results based on data from our clinical trials. These clinical trials are ongoing and this presentation does not speak to, and you should make no assumptions about, any additional data. In addition, the information we have chosen to publicly disclose regarding our product candidates has been selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise. If the initial data that we report differ from updated, late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.

This presentation discusses certain investigational therapeutic agents which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidate for the therapeutic use for which it is being studied.

This presentation contains statistical data based on independent industry publications or other publicly available information, as well as other information based on our internal sources. We have not independently verified the accuracy or completeness of the data contained in these industry publications and other publicly available information. Accordingly, we make no representations as to the accuracy or completeness of that data.


Except as required by law, we undertake no obligation to update any statements in this presentation for any reason after the date of this presentation. We have filed Current Reports on Form 8-K, Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and other documents with the SEC. You should read these documents for more complete information about us. You may obtain these documents for free by visiting EDGAR on the SEC website at <u>www.sec.gov</u>.



Alector Value Proposition: Pioneering Immuno-neurology

BOLD VISION	Realize a world where we made brain disorders history					
INNOVATIVE SCIENCE	Proprietary pipeline of novel immuno-neurology drugs					
ANTICIPATED DATA	AL002 INVOKE-2 Phase 2 data readout for early AD in Q4 20	024				
WELL RESOURCED	Experienced team, global partnerships and financial resources					
IMMUNOLOGY HUMAN GENETICS	NEUROSCIENCE Dysfunctional and damaging Microglia Healthy dise fighting Micro					
alector	Property	of Alector 3				

Science: Our Integrated Insights in Immuno-neurology



1. Bellenguez C, et al. Nature Genetics. 2022;54:412-436.; ©2022 Bellenguez C et all. Originally published in Nature Genetics.

alector

2. Wang, H., et al. Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression. J Neuroinflammation 19, 132 (2022).

alector 3. Liaury, K., et al. Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model. *J Neuroinflammation* 9, 56 (2012).; Cserép C, Schwarcz AD, et al. Microglial control of neuronal development via somatic purinergic junctions. *Cell Rep*. 2022 Sep 20;40(12):111369.

Well Resourced: Advancing Novel First-in-Class¹ Programs in Collaboration with **Established Global Partners**

TARGET	CANDIDATE	RESEARCH	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	ALECTOR'S COMMERCIAL OWNERSHIP	PARTNERS				
PGRN	Latozinemab	FTD-GRN					FTD-GRN				U.S. 50-50 profit share with co-promote and	GSK
	AL101	AD		> tiere			tiered double-digit royalties ex-U.S.	GSK				
TREM2	AL002	AD			\rangle	Global 50-50 profit share with opt-in	abbvie					
UD	ADP054-ABC	ALS, AD, PD	\rangle									
UD	UD-ABC	AD, PD	\rangle	•	contains 50+ pat							
GCase	ADP050-ABC	PD, LBD	\rangle	pending pate	de 79 issued pate nt applications di	alector						
GPNMB	ADP027-ABC	PD	\rangle	than 20 t	argets and/or teo							
UD	ADP056-ABC	AD	\rangle									

\$620 MILLION² IN CASH PROVIDES RUNWAY THROUGH 2026

1. Alector is not aware of any other TREM2-activating candidates in a Phase 2 or a Phase 3 trial for AD, PGRN-elevating candidates in a Phase 3 trial for FTD, or PGRN-elevating candidates in a Phase 2 or Phase 3 trial for AD as of February 2024. alector

ALS = amyotrophic lateral sclerosis, AD = Alzheimer's disease PD= Parkinson's disease, LBD = Lewy body disease Property of Alecto ABC = Alector Brain Carrier Technology UD = undisclosed

2. Cash, cash equivalents, and marketable securities as of December 31, 2023 were \$548.9 million plus net proceeds from January 2024 equity offering

AL002 (TREM2 Activator): A Promising Immuno-neurology Candidate for Early AD

THE HYPOTHESIS	POTENTIAL THERAF	PEUTIC BENEFITS*	AL002 STATUS
Increased TREM2 signaling may recruit microglia to broadly	Broad mechanism suggests potential for superior stand- alone therapy	Potential for clinical efficacy at multiple disease stages	 Completed enrollment in Phase 2 trial Data expected in Q4 2024 Currently over 90% of eligible participants who completed the planned treatment period have rolled over into the LTE portion Most advanced TREM2-activating
counteract progression of AD	Potential for superior clinical efficacy in combination with anti-Aβ antibodies	Potential for clinical efficacy independent of Aβ removal	 candidate in clinical development for AD¹ Modulates multiple biomarkers for microglia activity Treatment-emergent ARIA-like MRI findings AbbVie opt-in decision early 2025 with potential \$250M payment


alector^{**} *Pending further research and validation

1. Alector is not aware of any other TREM-2 activating candidates in a Phase 2 or Phase 3 trial for AD as of January 15, 2024.

TREM2: A Key Microglia Activating Immune Checkpoint/Immuno-neurology Receptor

TREM2 IS A KEY MICROGLIA SIGNALING RECEPTOR

- TREM2 is a damage-sensing receptor¹
- Sustains microglia response to brain injury¹
- Stimuli include apoptotic cells, cellular debris, myelin damage, and misfolded proteins (including Aβ)¹
- Regulates microglia survival proliferation, migration, and function¹






alector 1. Gratuze, M, et al., New insights into the role of TREM2 in Alzheimer's disease. *Mol Neurodegeneration* 13, 66 (2018).

©2018 Gratuze M et al. Originally published in Molecular Neurodegeneration.

TREM2 IS A KEY GENETIC RISK FOR AD

- Homozygous mutations cause dementia (NHD, FTD)²
- Heterozygous mutations increase risk for AD by as much as threefold²
- 40 TREM2 mutations related to AD have been identified²
- May modify the risk of developing PD and ALS²




2. Mutations TREM2 | Alzforum. (n.d.). Retrieved November 29, 2023, from https://www.alzforum.org/mutations/trem2

Copyright © 2023 AlzForum Foundation Inc. All Rights Reserved. Version 1.4.

Higher Levels of sTREM2: Associated with Slower Cognitive Decline in AD with Both Aβ and Tau Pathology

Potential for TREM2 modulation to provide benefit in later stages of disease when tau is present




alector Ewers, M, et al., *Sci Transl Med*. 2019 Aug 28;11(507):eaav6221. Requested from Publisher on 11/30/23.

High Levels of TREM2/sTREM2: Associated with Slower Accumulation of Tau


High levels of TREM2, as measured by sTREM2 in the CSF at baseline, predicted slower accumulation of aggregated tau in Braak III-VI regions over a four-year follow-up period

l alector



Property of Alector


AL002: A TREM2 Activating Antibody That Shows Multiple Downstream Effects



Opportunity: Explore Combination with Anti-Amyloid Beta Antibodies


"TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance" EMBO Molecular Medicine, 2016

Phagocytosis of $fA\beta_{42}$ by primary microglia from wt and *TREM2* KO animals in the presence or absence of mAb11, or an isotype control antibody¹




2. Alector data on file.


Aβ plaques staining from APP/PS1 mice that were treated with anti-amyloid antibodies with or without functional TREM2¹



Aducanumab reduces soluble Aβ (red vs. green bars) TREM2 agonist further reduces soluble Aβ (brown vs. red bars)²



AL002: Phase 1 Study in Healthy Volunteers




System Organ Class Preferred Term	AL002 0.003- 0.2 mg/kg (n=3) n (%)	AL002 0.6 mg/kg (n=6) n (%)	AL002 2 mg/kg (n=6) n (%)	AL002 6 mg/kg (n=6) n (%)	AL002 15 mg/kg (n=6) n (%)	AL002 30 mg/kg (n=6) n (%)	AL002 45 mg/kg (n=6) n (%)	AL002 60 mg/kg (n=14) n (%)	Pooled Placebo (n=11) n (%)
Participants with ≥1 TEAE	2 (66.7%)	3 (50.0%)	2 (33.3%)	5 (83.3%)	5 (83.3%)	4 (66.7%)	6 (100.0%)	10 (71.4%)	9 (81.8%)
Participants with ≥1 treatment- related TEAE ^b	2 (66.7%)	2 (33.3%)	2 (33.3%)	2 (33.3%)	2 (33.3%)	4 (66.7%)	5 (83.3%)	7 (50.0%)	6 (54.5%)
Treatment-related TE	AEs in ≥5% of	participants	in the total A	L002 group					
Headache	1 (33.3%)	1 (16.7%)	2 (33.3%)	2 (33.3%)	1 (16.7%)	4 (66.7%)	2 (33.3%)	2 (14.3%)	4 (36.4%)
Dizziness postural	1 (33.3%)	0	1 (16.7%)	0	0	1 (16.7%)	0	0	1 (9.1%)
Nausea	0	0	1 (16.7%)	1 (16.7%)	0	0	1 (16.7%)	6 (42.9%)	2 (18.2%)
Vomiting	0	0	0	0	0	0	0	3 (21.4%)	2 (18.2%)
Any TEAE leading to study drug withdrawal	0	0	0	0	0	0	1 (16.7%)	1 (7.1%)	0

Well Tolerated in Healthy Volunteers


I alector No drug-induced or drug-related Serious Adverse Effects or Dose Limiting Toxicity occurred

AL002: Target Engagement and Evidence of Microglia Activation Observed in Phase 1

TARGET ENGAGEMENT



Dose-Dependent Elevation in CSF sCSF-1R (Mean +-SD), Associated with Microglia Activation^{1,2}




alector Data are presented as mean ±SD; cohort n = 6 (placebo, 6 mg/kg, 15 mg/kg, 30 mg/kg) and 5 (45 mg/kg, 60 mg/kg). ***P = 0.0001 for 6 mg/kg and P < 0.0001 for all other doses vs. pooled placebo control. *P = 0.026 at 60 mg/kg vs. pooled placebo. ¹Phase 1 data presented at AAIC 2021; NCT03635047. ²Wang S et al. *J Exp Med*. 2020;217(9):e 20200785. **Consistent with preclinical results.


INVOKE-2: AL002 Phase 2 Study in Participants with Early Alzheimer's Disease

Phase II Design: Randomized, double-blind, placebo-controlled 4-arm, common close study (48-96 weeks); randomized 381 participants (1:1:1:1) with early Alzheimer's disease





Placebo





INVOKE-2: Clinical and Functional Outcome Measures

PRIMARY OUTCOME MEASURE	SECONDARY CLI FUNCTIONAL O MEASUI	ОИТСОМЕ	PROPORTIONAL ANALYSIS
 Clinical Dementia Rating Scale – Sum of Boxes Primary endpoint of lecanemab Phase 3 trials 	 RBANS ADAS-Cog 13 ADCS-ADL-MCI MMSE 	Items extracted for the iADRS, the primary endpoint of the donanemab Phase 3 trial	 Enables using ALL of the data collected in this common close design trial Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease Muture Common Co

iADRS = Integrated Alzheimer's Disease Rating Scale RBANs= Repeatable Battery for the Assessment of Neuropsychological Status ADCS-ADL-MCI = Activities of Daily Living for Mild Cognitive Impairment MMSE = Mini-Mental State Examination

alector

11

INVOKE-2: Biomarkers of Target Engagement, Microglial Signaling and AD Pathophysiology

TARGET ENGAGEMENT AND MICROGLIAL SIGNALING			ALZHEIMER'S DISEASE PATHOPHYSIOLOGY			
CSF sTREM2	CSF markers of Microglial Signaling		•	Amyloid/Tau Pathology		Neuronal and Synaptic injury
Reflects levels of TREM2 on microglial membrane	CSF-1R: Microglial proliferation		Amyloid PET Tau PET		Plasma GFAP CSF YKL40	Nfl Neurogranin
Lower levels of sTREM2 correlate with AL002			Plasma pTau ²¹⁷ CSF/Plasma pTau ^{MTBR}			Total Tau Volumetric MRI
binding and receptor internalization	IL1-RN: Microglial imr regulation	nune	CSF/Plasma Aß 42/40			
i alector	Markers of microglial subtypes / activity		ulating factor 1 receptor -1 receptor antagonist y acidic protein	(Y), lysine (K) and le NfL = neurofilamen	ned YKL-40 based on its three N-ter eucine (L), and its molecular mass of t light chain ementia Rating Sum Boxes	

ARIA: Treatment-related MRI Findings Resembling Amyloid Related Imaging Abnormalities Occurred in a Subset of Participants in the INVOKE-2 Trial

- MRI findings resemble ARIA reported with antiamyloid antibodies regarding:
 - MRI features, incidence, timing of onset/resolution, relatedness to number of ApoE ε4 alleles
 - Frequency and spectrum of clinical manifestations
- ApoE ε4/ε4s were voluntarily excluded from study:
 - ARIA incidence and radiographic severity were reduced after exclusion of ApoE ε4/ε4
- Most participants with radiographic ARIA in the trial population (excludes ApoE ε4/ε4) have been asymptomatic and clinically serious cases have been uncommon.
- Data Monitoring Committee regularly reviews data

ARIA-E	ApoE ε4/ε4 [†]	Current Study Population (Non–ApoE ε4/ε4)
ARIA-E incidence, n/N (%)	8/15 (71)*	49/337 (19)*
Radiographic severity (scale of 1-5), mean (SD)	2.5 (1.6)	2.2 (1.3)
ARIA-H	ΑροΕ ε4/ε4 ⁺	Current Study Population (Non–ApoE ε4/ε4)
ARIA-H incidence, n/N (%)	8/15 (71)*	57/337 (23)*
ARIA-H radiographic severity (%)		
Mild	1/8 (12.5)	25/57 (44)
Moderate	2/8 (25)	16/57 (28)
Severe	5/8 (62.5)	16/57 (28)

Symptomatic ARIA in Current Trial Population ⁺				
Total participants dosed (excluding ApoE $\epsilon 4/\epsilon 4)^{\dagger}$	337			
Participants with ARIA-E (%)	49 (19)*			
Asymptomatic (%)	43/49 (88)			
Symptomatic (%)	6/49 (12)			
Clinically serious ARIA (%)	2/337 (<1)			

This study remains blinded to treatment assignment.



INVOKE-2: What Are Our Goals for AL002 in the Long-Term and from the Trial?

- Therapeutic restoration of microglial function by AL002 may slow Alzheimer's disease progression by:
 - Enhancing the clearance of misfolded proteins, including amyloid
 - Enhancing other beneficial effects of microglia on brain health:
 - Maintenance of synaptic connections, support of astrocyte and oligodendrocyte function, maintenance and repair of the BBB and vasculature, and preservation of immune tolerance
- This may be demonstrated in our ongoing INVOKE-2 trial by evidence of treatment-related slowing of Alzheimer's disease progression across a combination of clinical, functional and biomarker readouts
- Given the multiple mechanisms by which healthy microglia protect the brain against neurodegenerative diseases, by the end of development, we believe AL002 has the potential to ultimately display better efficacy than current therapies that target individual misfolded proteins
- With its broad MOA, we believe AL002 has the potential to act either as a stand-alone therapy or in combination with anti- A β therapies



INVOKE-2: What Are Our Goals for AL002 in the Long-Term and from the Trial?

- Hypothesized potential differences from anti-amyloid trials with regard to:
 - Biomarker responses:
 - E.g., lowering cerebral amyloid PET signal to the 20-30 centiloid threshold for clinical efficacy may not be necessary for the MOA of AL002 which goes beyond amyloid clearance
 - Optimal disease stage(s) for intervention may be broader:
 - Given the broad MOA, we do not expect the beneficial effects of healthy microglia to be limited to specific pathophysiological stages of disease, and thus may include patients with preclinical AD to advanced dementia
 - Temporal dynamics of treatment effects may be broader:
 - Some effects of improved microglia function may manifest early in treatment (e.g., amyloid clearance, maintenance of synaptic function), while others may become apparent later (e.g., support of astrocyte and oligodendrocyte function, repair of vasculature and BBB). This may not be fully appreciated early in treatment and may be more evident in our LTE



AL002: Currently Partnered in an Option Agreement with AbbVie

abbvie 📑

AL002

\$205M upfront payment (2017 and 2018)
\$20M equity investment (2018)
\$17.8M milestone payment received (2023)
\$12.5M received in support of enrollment (2023)
\$250M if opt-in decision (anticipated early 2025)
\$225M in potential additional milestones
Global 50-50 profit share




Latozinemab and AL101: Promising PGRN-Elevating Candidates for Neuro-degeneration

THE HYPOTHESIS	POTENTIAL THERAPEUTIC BENEFITS	LATOZINEMAB STATUS
PGRN elevation may promote neuronal and microglia survival and functionality to counteract neurodegeneration	Potential for efficacy as stand-alone therapy and/or in combination with other therapies	 Achieved target enrollment in pivotal Phase 3 clinical trial in FTD-GRN Most advanced PGRN-elevating candidate in clinical development for FTD¹ Granted Orphan Drug Designation for FTD as well as Breakthrough
		Therapy and Fast Track designations for FTD-G <i>RN</i> AL101 STATUS
	Potential for clinical benefit in multiple neurodegenerative diseases at broader stages	 Dosed first participant in global Phase 2 trial in early AD
		 Most advanced, PGRN-elevating candidate in clinical developmen for AD¹

1. Alector is not aware of any other PGRN-elevating candidates in a Phase 3 trial for FTD or in a Phase 2 or Phase 3 trial for AD as of February 2024.

PGRN = progranulin protein

GRN Mutations: Causal or Increase Risk for Multiple Neurodegenerative Diseases



Rhinn H, et al. Trends Pharmacol Sci. 2022;43(8):641-652.

alector Nalls MA, et al. Brain Commun. 2021;3(2):fcab095. Sheng J, et al. Gene. 2014;542(2):141-145.

Kumar-Singh S. J Mol Neurosci. 2011;45:561-573.

Paushter DH, et al. Acta Neuropathol. 2018;136(1):1–17.

GRN = gene that encodes the protein progranulin

Frontotemporal Dementia (FTD): A Rapidly Progressive Form of Dementia, with No Approved Treatment



Tommy Nash Jr., with his daughter, Alyssa Nash. Tommy was diagnosed with FTD at 38 years old.¹

1. With permission from Tommy Nash Jr. and Alyssa Nash, May 2023 Greaves et al. *J Neurol.* 2019;266:2075-2086. Taylor RT, et al. *Pract Neurol.* 2019:72-77. Kansal K, et al. *Dement Geriatr Cogn Disord.* 2016;41:109-122. Boeve BF, et al. *Brain.* 2006;129:3103-3114. UCSF Weill Institute for Neurosciences Memory and Aging Center: Familial FTD **Prevalence:** Most common cause of dementia under age 60

Progression:

- Rapid progression of memory impairment, other cognitive functions
- Life expectancy after diagnoses is 7-10 years

Diagnosis:

- Compulsive behavior, lack of restraint, apathy, anxiety, and aphasia
- Symptoms typically begin between the ages of 45-64 years old
- Frequently misdiagnosed as AD, depression, PD, or psychiatric condition
- **Treatment:** No approved treatments to cure or slow progression of FTD

Forms:

- Sporadic FTD occurs without a clear familial or inherited pattern
- Genetic FTD occurs due to autosomal dominant mutations in one of three genes: *GRN*, *C9orf72* or *MAPT*




Latozinemab and AL101 : Pioneering Approach to Elevating Progranulin Levels With Potential to Enhance Microglial and Neuronal Function and Treat FTD and AD

PGRN: Genetic and Biologic Rationale

- **Genetics:** Mutations in PGRN are deleterious.
 - Homozygous (100% LOF): Neuronal ceroid lipofuscinosis with onset <25 years of age, 100% penetrance.
 - Heterozygous (50% LOF): Reduce progranulin levels to 50% of normal; Frontotemporal dementia with onset ~58 years of age, >90% penetrance.
 - Non-coding mutations (~10-20% LOF): Increase risk for ALS, FTD, AD, PD.
- Biology: PGRN is a critical immune regulator, neuronal survival factor and a lysosomal chaperone.

Latozinemab and AL101: PGRN Elevating Program



Latozinemab (AL001) and AL101 elevate PGRN levels by blocking sortilin (SORT1), a degradation receptor for PGRN

alector

Or Source: Alz Res Therapy 4, 4 (2012); Sci Transl Med. 2017 Apr 12;9(385); Dement Geriatr Cogn Disord Extra 2016;6:330-34.; Eur J Neurol. 2013 Dec;20(12):1571-3; Gene. 2014 Jun 1;542(2):141-5.

PGRN = progranulin proteinALS = amyotroplLOF = loss of functionAD = Alzheimer'sFTD = frontotemporal dementiaPD = Parkinson's

ALS = amyotrophic lateral sclerosis AD = Alzheimer's disease PD = Parkinson's disease

INFRONT-2: Phase 2 Trial in FTD

Open-Label, Single Arm

Asymptomatic FTD-GRN¹ N = 5

AL001 60 mg/kg q4w for 96 weeks

Symptomatic FTD-*GRN*¹ N = 12

alector[®]

AL001 60 mg/kg q4w for 96 weeks

Symptomatic FTD-*C9orf72*¹ N = up to 20

AL001 60 mg/kg q4w for 96 weeks

- 1. Asymptomatic and symptomatic FTD-GRN enrollment closed; FTD-C9orf72 cohort currently enrolling
- CDR[®] plus NACC FTLD-SB: Clinical Dementia Rating (CDR) dementia staging instrument plus National Alzheimer's Coordinating Center (NACC) behavior and language domains frontotemporal lobar degeneration (FTLD) sum of boxes (SB)

AL001 = latozinemab FTD = frontotemporal dementia GRN = granulin gene C9orf72 = chromosome 9 open reading frame 72 gene PK = pharmacokinetic, PD = pharmacodynamic CSF = cerebrospinal fluid

PRIMARY ENDPOINT

Safety and Tolerability

SECONDARY ENDPOINT

PK, PD

EXPLORATORY ENDPOINTS

CSF and Plasma Biomarkers (Lysosomal, inflammation, neurodegeneration)

Volumetric MRI (vMRI)

Clinical Outcome Assessment (CDR[®] plus NACC FTLD-SB²)

INFRONT-2: Clinical Outcome Assessments Supported by Biomarkers in FTD-GRN

Key biomarkers and clinical outcome assessments reflect underlying disease activity in FTD-GRN patients


TARGET ENGAGEMENT		CLINICAL BENEFIT			
PGRN (Plasma and CSF)	Lysosomal Dysfunction	Inflammation	Brain Health	Brain Atrophy	Clinical Outcome Assessments
PGRN CSF and plasma	e.g. CTSD , LAMP1 Dysfunctional	e.g. C1QB Elevation of	GFAP Elevation of	MRI Accelerated	CDR [®] plus NACC FTLD-SB FDA approvable
PGRN levels	lysosomes are hallmarks of FTD- <i>GRN</i>	complement proteins occurs in FTD- <i>GRN</i>	GFAP is a hallmark of FTD- <i>GRN</i> correlates with cognitive decline	brain tissue loss is a hallmark of FTD- <i>GRN</i> and correlates with cognitive decline	endpoint for measuring clinical decline in FTD




CTSD = cathepsin D; LAMP1 = lysosomal associated membrane protein 1; C1QB = complement C1q B chain; GFAP = glial fibrillary acidic protein CDR[®] plus NACC FTLD-SB = Clinical Dementia Rating (CDR) dementia staging instrument plus National Alzheimer's Coordinating Center (NACC) behavior and language domains frontotemporal lobar degeneration (FTLD) sum of boxes (SB)

INFRONT-2: Latozinemab Restores PGRN in Plasma and CSF to Levels Seen in Healthy Volunteer Age-Matched Controls

ACHIEVED PGRN RESTORATION IN FTD-GRN PARTICIPANTS






PGRN CSF Concentration

INFRONT-2: Latozinemab Treatment Decreases Glial Fibrillary Acidic Protein (GFAP) Levels Towards Range Seen in Asymptomatic Carriers of FTD-*GRN* Mutation

BIOMARKERS OF DISEASE ACTIVITY – ASTROGLIOSIS




1. Range is of baseline GFAP levels in asymptomatic FTD-GRN patients enrolled in INFRONT-2 Source: AAIC 2021.

INFRONT-2: Encouraging Trends Across Biomarkers Of Disease Activity

SYMPTOMATIC FTD-GRN PARTICIPANTS AT 12 MONTHS IN OPEN LABEL TRIAL

LYSOSOMAL AND INFLAMATORY BIOMARKERS

BRAIN VOLUME CHANGES BIOMARKERS



Normalization of lysosomal and inflammatory biomarkers


Markers	Latozinemab Baseline (N=9)	Latozinemab 6 months (N=8)	Latozinemab 12 months (N=8)	Age-matched procured control (N=44)
CTSD (fm/μL)	5.2 (1.16)	3.8 (0.57)	3.1 (0.21)	3.4 (0.08)
LAMP1 (fm/µL)	0.6 (0.12)	0.4 (0.06)	0.4 (0.043)	0.4 (0.01)
C1QB (fm/µL)	0.7 (0.12)	0.6 (0.07)	0.5 (0.02)	0.5 (0.02)

Mean +/- SEM

CTSD = cathepsin D protein




LAMP1= lysosomal-associated membrane protein 1 C1QB = gene that encodes the B-chain polypeptide of serum complement subcomponent C1q



* n=8 for Whole Brain, n=7 for TBM measures (TBM measures were not available for one GENFI2 participant). One GENFI2 subject was excluded from the analysis as the patient displayed cortical volume increases (2.58% annual volume increase in the FT cortex) indicating image analysis artifact

INFRONT-2: Preliminary Data Suggests Latozinemab May Slow Disease Progression in FTD-GRN Participants Compared to Matched Historical Controls

CLINICAL MEASURE



CDR® plus NACC FTLD-SB


 Random Coefficient Model with Repeated Measurements including baseline & all available post-baseline measurements up to 12 months. Data cut-off Sep 8, 2021.
 Phase 2 data presented at CTAD 2021 and ADPD 2022

alector

NCT03987295

GENFI2 refers to the longitudinal FTD registry dataset

INFRONT-3: Ongoing Pivotal Phase 3 Study with Latozinemab





"At risk" = GRN carriers who are pre-symptomatic and meet a pre-specified NfL threshold for enrollment in the Phase 3 CDR® plus NACC FT1. LD-SB = Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center Frontotemporal Lobar Degeneration Behavior and Language Domains Sum of Boxes; CGI-S = Clinician's Global Impression-Severity; CGI-I = Clinician's Global Impression-Improvement; FRS = Frontotemporal Dementia Rating Scale; RBANS = Repeatable Battery for the Assessment of Neuropsychological Status

AL101/GSK4527226: Developed to Align with Needs of Larger Indications (AD)

PGRN: Genetic and Biologic Rationale for AD

- **Genetics:** PGRN deficiency is a risk for AD.
- **Biology:** Modulation of PGRN in AD disease models.
 - PGRN ablation exacerbates AD in disease models.
 - PGRN overexpression is protective in AD disease models.

- AL101 AD Program
- **Phase 1:** Completed in healthy volunteers.
- **Phase 2:** Received IND clearance from FDA in AD.
- **Phase 2:** Dosed first participant in global early AD study.




Mendsaikhan, A., et al. Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology. *acta neuropathol commun 7, 215 (2019). The breakdown of clinical diagnoses among ARTFL FTD mutations carriers. [Courtesy of Adam Boxer.] <u>https://www.alzforum.org/print-series/1093496</u>; Bellenguez C, Küçükali F, Jansen I, et al. New insights on the genetic etiology of Alzheimer's and related dementia. medRxiv; 2020.*

PGRN = progranulin protein LOF = loss of function AD = Alzheimer's disease

AL101/GSK4527226 PROGRESS-AD Study Design

PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL101/GSK4527226 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE



Key inclusion criteria

- Age 50-85 years, inclusive
- Diagnosis of MCI due to AD up to mild AD dementia
- Amyloid positivity (by PET or CSF)

Primary endpoint

Change from Baseline in CDR-SB across Weeks 52, 64 and 76.

Key secondary endpoints

Change from Baseline across Weeks 52, 64 and 76 for iADRS, ADAS-Cog14, ADCS-iADL, ADCS-ADL-MCI, ADCOMS

Biomarkers: Amyloid PET, Tau PET, CSF and Plasma



Latozinemab and AL101: Currently Partnered in a Collaboration Agreement with GSK

Latozinemab and AL101

\$700M upfront (2021 and 2022)
\$1.5B+ in potential milestone payments
U.S. 50-50 profit share
Tiered double-digit royalties ex-U.S.
\$160 million for first commercial sale in the U.S.
\$90 million for first commercial sale in at least
two of the following countries: France,
Germany, Italy, Spain, or the UK




GSK

Science: Proprietary Drug Discovery Platform Driving Novel Drug Candidates

OUR ADVANTAGE


Knowledge and expertise of how to connect these efforts efficiently to produce viable product candidates



alector^{*} PheWAS = Phenome-Wide Association Study

Alector Brain Carrier Technology

SELECTIVELY DEPLOYING PROPRIETARY ABC TECHNOLOGY ON NEXT GENERATION PROGRAMS



ABC toolbox optimized to cargo

- scFv, Fab or VHH
- affinity
- valency

Key Advantageous Features

Diverse BBB targets with best-in-class BBB penetration efficacy

- Achieve >10-fold increase in brain concentrations and deep brain penetration
- Optimize for target MOA and cell types

• Versatile bispecific formats

- Brain Carrier formats as Fab, scFv, VHH with any multi-specific fusion formats
- Adaptable Fc for optimizing effector function, half-life, single-chain

• Equivalent human/cyno affinities


• Translatability of safety and efficacy studies in NHP

• Broad set of affinity variants with matched murine surrogates

- Balancing brain uptake with peripheral clearance and safety profile
- Good safety profiles, even with active Fc

Anti-TfR ABC: Increased Brain Uptake in Mice

• >10x increase in vessel depleted brain uptake seen in mice



alector[•] TfR = transferrin receptor ABC = Alector Brain Carrier Visualized post-intravenous dosing

Alector Value Proposition: Aims to Deliver Innovation To Make Brain Disorders History

Accomplishments to date

Pioneering firsts for patients

- AL001 (latozinemab) first anti-SORT1 molecule in FTD-GRN¹
- Achieved target enrollment in latozinemab FTD-GRN pivotal P3
- AL002 first TREM2 molecule in AD1
- Completed enrollment in AL002 AD P2
- Dosed first participant in AL101 AD Ph 2
- Pipeline of first-in-class approaches for brain disorders¹

Goals for Next 3 years

Aim to deliver firsts for patients

- **Deliver data** for AL002 P2 and latozinemab pivotal P3
- Complete enrollment of AL101 AD P2
- Deliver blood brain barrier platform technology to enhance our novel programs
- Deliver 2-3 first-in-class leads for IND enabling studies

Goals for 3+ years

Aim to make brain disorders history

- Obtain regulatory approval and commercialize latozinemab in FTD-GRN
- Deliver data for AL101 Phase AD P2
- Launch our initial first-in-class AD programs with partners globally*
- Continue to advance our pioneering science from research to the clinic with multiple INDs for novel programs

\$620 MILLION² IN CASH PROVIDES RUNWAY THROUGH 2026



1. Alector is not aware of any other TREM2-activating candidates in a Phase 2 or a Phase 3 trial for AD, PGRN-elevating candidates in a Phase 3 trial for FTD, or PGRN-elevating candidates in a Phase 2 or Phase 3 trial for AD as of January 15, 2024.

AD = Alzheimer's disease FTD = Frontotemporal dementia GRN = granulin gene Property of Alector *Assuming regulatory approval

38

2. Cash, cash equivalents, and marketable securities as of December 31, 2023 were \$548.9 million plus net proceeds from January 2024 equity offering.



Thank You